Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06478862 |
| Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy |
| terminated |
| Phase 2 |
| 19 |
| Lipomedix Pharmaceuticals Inc.INDUSTRY |
| 1 |
| Jan 9, 2026 |
| clinicaltrials |
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 21 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | terminated | Phase 2 | 6 | Chloe Atreya, MD, PhDOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04203160 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | terminated | Phase 1 / Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | terminated | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | terminated | Phase 2 | 10 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | terminated | Phase 2 | 9 | Ludwig-Maximilians - University of MunichOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | terminated | Phase 2 | 4 | Lahey ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma(CLAUDIO-01) | terminated | Phase 1 / Phase 2 | 31 | SOTIO Biotech a.s.INDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 1 | BioNTech SEINDUSTRY | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract | terminated | Phase 2 | 13 | American Regent, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | terminated | Phase 2 | 46 | Vall d'Hebron Institute of OncologyOTHER | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer(CLAUDE) | terminated | Phase 2 | 1 | EnteromeINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | terminated | Phase 2 | 47 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer(COCHISE) | terminated | Phase 2 | 18 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | terminated | Phase 2 | 18 | University Health Network, TorontoOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05619172 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | terminated | Phase 2 | 16 | SOTIO Biotech AGINDUSTRY | 3 | Jul 24, 2025 | clinicaltrials |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | terminated | Phase 2 | 17 | Patrick BolandOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | terminated | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | terminated | Phase 2 | 6 | University of FloridaOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)(ELEVATE CRC) | terminated | Phase 2 | 77 | Gilead SciencesINDUSTRY | 10 | Jul 1, 2025 | clinicaltrials |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC | terminated | Phase 2 | 1 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy | terminated | Phase 1 / Phase 2 | 31 | Nerviano Medical SciencesINDUSTRY | 3 | Jun 19, 2025 | clinicaltrials |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04479436 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | terminated | Phase 2 | 40 | Daiichi SankyoINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | terminated | Phase 2 / Phase 3 | 62 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials